Hubei Xiaogan Manufacturing Site
Porton acquired this site in 2021. Covering a total area of 221,200 square meters, it is dedicated to the research, development, and production of pharmaceutical intermediates.
No.1 Fazhan Road, Changjiangbu District, Yingcheng, Hubei
2013Years
546m3Total Capacity
Capability
- ISO Site
- Primary IM
- API Starting Material
- Grignard, Bromination, c-c coupling, Cyanidation etc
- Temperature Range (-70~140℃)
- Flow Chemistry
Services
Small Molecule
Small Molecule
Porton offers efficient, flexible, and high-quality solutions for custom development and production of small molecule APIs, as well as technical services throughout the entire lifecycle from pre-clinical to commercial to our worldwide partners.
One Porton One Quality
Compliance standards, Continuous improvement, Customer oriented
Quality management runs throughout the entire process of the drug life cycle. The quality management system of the drug product site is built in accordance with international standards and continues to adhere to the quality concept of 'more well-established system, more controllable quality.' This ensures that the GMP activities of the drug product site meet the requirements of international quality management systems and market drug regulatory agencies, including those of China, the European Union, FDA, and other mainstream regulations.
Case Studies
Continuous Improvement of Project Life Cycle Management, Benefiting Customers by Reducing Total Cost
Molecular Modeling and Data Science for De-risking and Cost- saving of Pharmaceutical Development
Agile and Fast：Enabling Rapid Market Launch of Innovative Drugs from Preclinical to Commercialization in 18 Months
News
MoreNews2025-01-03
Porton Achieves Higher Scores in the 2024 S & P Global ESG Assessment
More
News2024-12-19
Porton Newsletter | Q4 2024 Recap
More
News2024-12-06
Porton Recognized as an Exemplary Case for Sustainable Development
More
News2024-12-06
Porton is thrilled to announce the launch of its newly redesigned official website
More
News2024-10-01
Porton Newsletter | Q3 2024 Recap
More
